Scilex Holding (SCLX) Income from Non-Controlling Interests (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Income from Non-Controlling Interests of -$2.4 million for Q1 2026, down 116.85% quarter-over-quarter from $14.1 million in Q4 2025.
Scilex Holding (SCLX) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Scilex Holding's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$2.4 million for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests changed N/A year-over-year to -$2.4 million; the TTM figure through Mar 2026 stood at $9.4 million (changed N/A YoY), while the FY2025 annual figure was $11.8 million, changed N/A from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$2.4 million, down from $14.1 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $14.1 million in Q4 2025, with the low at -$2.4 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 10.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 741.95 Mn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.38 Mn |
| Dec 31, 2025 | 14.13 Mn |
| Sep 30, 2025 | -586,000.00 |
| Jun 30, 2025 | -1.74 Mn |
| Mar 31, 2021 | 1.33 Mn |